Online telehealth company Hims & Hers Health , seeking growth drivers as its original sexual-health franchises matured, may have overstepped with a risky launch of weight-loss pills that drew swift blowback from Danish drugmaker Novo Nordisk and U.S. regulators.

Add Reuters to Your Google Preferred Sources

 

Reuters Business

Reuters Business

 

Hims & Hers GLP-1 pill gambit backfires, accelerating crackdown on drug compounders 

 

US automakers caught in crossfire of Trump, California EV battle 

 

Morning Bid: Oil spoils tech tonic 

 

ECB's Lagarde signals no imminent exit as politics and central banks collide 

 

Oil companies jostle for projects to boost Venezuelan output quickly; a real grind awaits 

 

Bill Gates pulls out of India AI summit; anger mounts over organisational lapses 

 

US stock futures stall after recent gains, Walmart's disappointing outlook 

 

Walmart CEO Furner begins tenure with conservative outlook 

 

How China plans to dominate global trade long after Trump 

 

American Airlines picks CFM International to power upcoming Airbus A321neo jets 

 

Sponsors are not involved in the creation of newsletters or other Reuters news content. Advertise in this newsletter or on Reuters' website

LiveIntent Logo
AdChoices Logo
 

Reuters Business is sent every weekday. Think your friend or colleague should know about us? Forward this newsletter to them. They can also sign up here.

Want to stop receiving this email? Unsubscribe here. To manage which newsletters you're signed up for, click here.

This email includes limited tracking for Reuters to understand whether you’ve engaged with its contents. For more information on how we process your personal information and your rights, please see our Privacy Statement.

Terms & Conditions

 

© 2026 Thomson Reuters. All rights reserved.
3 Times Square, New York, NY 10036

fb ig x